Published in J Occup Environ Med on June 01, 2005
Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes. Mol Psychiatry (2009) 3.56
European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry (2010) 2.53
Validity of the World Health Organization Adult ADHD Self-Report Scale (ASRS) Screener in a representative sample of health plan members. Int J Methods Psychiatr Res (2007) 1.87
Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry (2010) 1.81
Structure and diagnosis of adult attention-deficit/hyperactivity disorder: analysis of expanded symptom criteria from the Adult ADHD Clinical Diagnostic Scale. Arch Gen Psychiatry (2010) 1.68
The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative. Occup Environ Med (2008) 1.59
Response variability in Attention-Deficit/Hyperactivity Disorder: a neuronal and glial energetics hypothesis. Behav Brain Funct (2006) 1.57
Multicenter analysis of the SLC6A3/DAT1 VNTR haplotype in persistent ADHD suggests differential involvement of the gene in childhood and persistent ADHD. Neuropsychopharmacology (2009) 1.33
Simulated driving performance of adults with ADHD: comparisons with alcohol intoxication. Exp Clin Psychopharmacol (2008) 1.23
A population-based study of attention deficit/hyperactivity disorder symptoms and associated impairment in middle-aged adults. PLoS One (2012) 1.13
Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology (Berl) (2007) 1.12
Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. J Am Acad Child Adolesc Psychiatry (2011) 1.10
Attention Deficit Hyperactivity Disorder (ADHD) among longer-term prison inmates is a prevalent, persistent and disabling disorder. BMC Psychiatry (2010) 1.09
Who cares for patients with attention-deficit/hyperactivity disorder (ADHD)? Insights from Nordbaden (Germany) on administrative prevalence and physician involvement in health care provision. Eur Child Adolesc Psychiatry (2007) 1.04
Anatomical and functional brain imaging in adult attention-deficit/hyperactivity disorder (ADHD)--a neurological view. Eur Arch Psychiatry Clin Neurosci (2006) 1.02
Childhood attention problems and socioeconomic status in adulthood: 18-year follow-up. Br J Psychiatry (2012) 1.01
Neural correlates (ERP/fMRI) of voluntary selection in adult ADHD patients. Eur Arch Psychiatry Clin Neurosci (2009) 0.99
Long-term consequences of childhood ADHD on criminal activities. J Ment Health Policy Econ (2009) 0.95
How do different diagnostic criteria, age and gender affect the prevalence of attention deficit hyperactivity disorder in adults? An epidemiological study in a Hungarian community sample. Eur Arch Psychiatry Clin Neurosci (2009) 0.92
Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. Psychopharmacology (Berl) (2011) 0.91
Treatment of adults with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat (2008) 0.90
Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry (2007) 0.90
Hippocampus and amygdala morphology in adults with attention-deficit hyperactivity disorder. J Psychiatry Neurosci (2008) 0.88
Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. Adv Ther (2013) 0.88
Long-term functional outcome in adult prison inmates with ADHD receiving OROS-methylphenidate. Eur Arch Psychiatry Clin Neurosci (2012) 0.87
Absence of association with DAT1 polymorphism and response to methylphenidate in a sample of adults with ADHD. Am J Med Genet B Neuropsychiatr Genet (2006) 0.87
Treatment strategies for co-occurring ADHD and substance use disorders. Am J Addict (2007) 0.87
Adolescent ADHD and adult physical and mental health, work performance, and financial stress. Pediatrics (2012) 0.87
Childhood and persistent ADHD symptoms associated with educational failure and long-term occupational disability in adult ADHD. Atten Defic Hyperact Disord (2014) 0.86
Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands. Atten Defic Hyperact Disord (2010) 0.86
Cost of illness and comorbidities in adults diagnosed with attention-deficit/hyperactivity disorder: a retrospective analysis. Prim Care Companion CNS Disord (2011) 0.84
Attention deficit hyperactivity disorder in Australian adults: prevalence, persistence, conduct problems and disadvantage. PLoS One (2012) 0.83
Work injury risk among young people with learning disabilities and attention-deficit/hyperactivity disorder in Canada. Am J Public Health (2009) 0.83
Methylphenidate off-label use and safety. Springerplus (2014) 0.83
Rates of undiagnosed attention deficit hyperactivity disorder in London drug and alcohol detoxification units. BMC Psychiatry (2012) 0.83
Motor regulation problems and pain in adults diagnosed with ADHD. Behav Brain Funct (2013) 0.82
Association study of promoter polymorphisms at the dopamine transporter gene in Attention Deficit Hyperactivity Disorder. BMC Psychiatry (2009) 0.82
Psychometric evaluation of the Sheehan Disability Scale in adult patients with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat (2014) 0.82
Psychiatric Disorders and Polyphenols: Can They Be Helpful in Therapy? Oxid Med Cell Longev (2015) 0.81
Psychiatric epidemiology: challenges and opportunities. Int Rev Psychiatry (2007) 0.81
Alpha-2 adrenergic receptors and attention-deficit/hyperactivity disorder. Curr Psychiatry Rep (2010) 0.79
A systematic review of global publication trends regarding long-term outcomes of ADHD. Front Psychiatry (2012) 0.79
Treatment of adults with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat (2008) 0.78
A controlled study of a simulated workplace laboratory for adults with attention deficit hyperactivity disorder. Psychiatry Res (2012) 0.78
Course of alcohol symptoms and social anxiety disorder from adolescence to young adulthood. Alcohol Clin Exp Res (2015) 0.77
Acute effects of methylphenidate on neuropsychological parameters in adults with ADHD: possible relevance for therapy. J Neural Transm (Vienna) (2008) 0.77
Prevalence of Adult Attention Deficit Hyperactivity Disorder (Adult ADHD): Tabriz. Iran J Psychiatry (2014) 0.76
Attention-deficit/hyperactivity disorder in childhood is associated with cognitive test profiles in the geriatric population but not with mild cognitive impairment or Alzheimer's disease. J Aging Res (2011) 0.76
The Wuerzburg Research Initiative on Adult Attention-Deficit/Hyperactivity Disorder (WURIN-AADHD): multi-layered evaluation of long-term course. Eur Arch Psychiatry Clin Neurosci (2006) 0.75
Is Work-Related Rumination Associated with Deficits in Executive Functioning? Front Psychol (2016) 0.75
Childhood attention deficit hyperactivity disorder, substance use, and adult functioning among incarcerated women. J Atten Disord (2009) 0.75
Diagnosis of ADHD and its Behavioral, Neurologic and Genetic Roots. Top Lang Disord (2012) 0.75
Attention-deficit hyperactivity disorder medication use: factors involved in prescribing, safety aspects and outcomes. Ther Adv Drug Saf (2016) 0.75
Prevalence and correlates of attention-deficit hyperactivity disorder symptoms in Korean college students. Neuropsychiatr Dis Treat (2015) 0.75
Self-Reported Mindful Attention and Awareness, Go/No-Go Response-Time Variability, and Attention-Deficit Hyperactivity Disorder. Mindfulness (N Y) (2016) 0.75
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry (2005) 58.92
The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). Int J Methods Psychiatr Res (2004) 29.02
The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry (2006) 11.85
Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey Initiative. World Psychiatry (2007) 6.46
The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med (2005) 5.81
Age of onset of mental disorders: a review of recent literature. Curr Opin Psychiatry (2007) 4.46
Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med (2006) 3.57
The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiol Psichiatr Soc (2009) 3.55
The prevalence of chronic pain in United States adults: results of an Internet-based survey. J Pain (2010) 3.51
Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry (2006) 3.47
Childhood adversities and adult psychopathology in the WHO World Mental Health Surveys. Br J Psychiatry (2010) 3.38
The impact of comorbidity of mental and physical conditions on role disability in the US adult household population. Arch Gen Psychiatry (2007) 3.15
Development of lifetime comorbidity in the World Health Organization world mental health surveys. Arch Gen Psychiatry (2011) 3.01
Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiatry (2005) 2.87
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry (2003) 2.66
Delay and failure in treatment seeking after first onset of mental disorders in the World Health Organization's World Mental Health Survey Initiative. World Psychiatry (2007) 2.63
The epidemiology of depression across cultures. Annu Rev Public Health (2013) 2.60
International Consensus Statement on ADHD. J Am Acad Child Adolesc Psychiatry (2002) 2.38
Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry (2002) 2.37
Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol (2004) 2.36
Disability and treatment of specific mental and physical disorders across the world. Br J Psychiatry (2008) 2.35
Adult psychiatric outcomes of girls with attention deficit hyperactivity disorder: 11-year follow-up in a longitudinal case-control study. Am J Psychiatry (2010) 2.31
Using the World Health Organization Health and Work Performance Questionnaire (HPQ) to evaluate the indirect workplace costs of illness. J Occup Environ Med (2004) 2.22
Diagnosing adult attention deficit hyperactivity disorder: are late onset and subthreshold diagnoses valid? Am J Psychiatry (2006) 2.03
The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry (2005) 2.03
Analysis of the effectiveness and cost benefit of leukotriene modifiers in adults with asthma in the Ohio Medicaid population. J Manag Care Pharm (2006) 2.00
Annual costs associated with diagnosis of uterine leiomyomata. Obstet Gynecol (2006) 1.96
Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry (2003) 1.91
Application of the International Classification of Functioning, Disability and Health (ICF) in clinical practice. Disabil Rehabil (2002) 1.91
Validity of pilot Adult ADHD Self- Report Scale (ASRS) to Rate Adult ADHD symptoms. Ann Clin Psychiatry (2006) 1.89
Validity of the World Health Organization Adult ADHD Self-Report Scale (ASRS) Screener in a representative sample of health plan members. Int J Methods Psychiatr Res (2007) 1.87
A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry (2005) 1.87
The World Health Organization World Mental Health Survey Initiative. Epidemiol Psichiatr Soc (2006) 1.76
Psychopathology in females with attention-deficit/hyperactivity disorder: a controlled, five-year prospective study. Biol Psychiatry (2006) 1.73
Young adult follow-up of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. J Abnorm Child Psychol (2002) 1.72
Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol (2009) 1.70
Structure and diagnosis of adult attention-deficit/hyperactivity disorder: analysis of expanded symptom criteria from the Adult ADHD Clinical Diagnostic Scale. Arch Gen Psychiatry (2010) 1.68
The relationship between technology availability and health care spending. Health Aff (Millwood) (2004) 1.65
Heterogeneity of irritability in attention-deficit/hyperactivity disorder subjects with and without mood disorders. Biol Psychiatry (2005) 1.62
Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder. J Pediatr (2009) 1.60
Attention-deficit/hyperactivity disorder: increased costs for patients and their families. J Am Acad Child Adolesc Psychiatry (2003) 1.55
Diagnostic controversies in adult attention deficit hyperactivity disorder. Am J Psychiatry (2004) 1.53
Long-term effects of extended-release mixed amphetamine salts treatment of attention- deficit/hyperactivity disorder on growth. J Child Adolesc Psychopharmacol (2005) 1.50
Social and emotional impairment in children and adolescents with ADHD and the impact on quality of life. J Adolesc Health (2010) 1.50
Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol (2004) 1.49
Associations of nonrestorative sleep with insomnia, depression, and daytime function. Sleep Med (2010) 1.48
Smoking and suicidal behaviors in the National Comorbidity Survey: Replication. J Nerv Ment Dis (2007) 1.42
Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry (2008) 1.41
Talking to families about ADHD. J Am Acad Child Adolesc Psychiatry (2004) 1.39
Impact of HIV/AIDS on care and outcomes of severe sepsis. Crit Care (2005) 1.32
Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol (2009) 1.32
Hyperactive children as young adults: driving abilities, safe driving behavior, and adverse driving outcomes. Accid Anal Prev (2006) 1.31
Executive functioning in hyperactive children as young adults: attention, inhibition, response perseveration, and the impact of comorbidity. Dev Neuropsychol (2005) 1.31
Productivity and medical costs of diabetes in a large employer population. Diabetes Care (2002) 1.30
Clinical utility of EEG in attention deficit hyperactivity disorder. Appl Neuropsychol (2005) 1.28
The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr (2004) 1.26
Integrated telehealth and care management program for Medicare beneficiaries with chronic disease linked to savings. Health Aff (Millwood) (2011) 1.26
Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder. CNS Spectr (2009) 1.25
Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population. Mayo Clin Proc (2009) 1.24
Substance use among ADHD adults: implications of late onset and subthreshold diagnoses. Am J Addict (2007) 1.22
Young adults with attention deficit hyperactivity disorder: subtype differences in comorbidity, educational, and clinical history. J Nerv Ment Dis (2002) 1.21
Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics (2009) 1.20
Growth deficits and attention-deficit/hyperactivity disorder revisited: impact of gender, development, and treatment. Pediatrics (2003) 1.18
Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes? J Child Adolesc Psychopharmacol (2006) 1.17
Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients. J Adolesc Health (2004) 1.17
Gray matter alterations in adults with attention-deficit/hyperactivity disorder identified by voxel based morphometry. Biol Psychiatry (2010) 1.15
Interstitial Cystitis: Cost, treatment and co-morbidities in an employed population. Pharmacoeconomics (2006) 1.14
Emotional dysregulation in adult ADHD and response to atomoxetine. Biol Psychiatry (2005) 1.12
Severity of the aggression/anxiety-depression/attention child behavior checklist profile discriminates between different levels of deficits in emotional regulation in youth with attention-deficit hyperactivity disorder. J Dev Behav Pediatr (2012) 1.12
ICD-11 for quality and safety: overview of the WHO Quality and Safety Topic Advisory Group. Int J Qual Health Care (2013) 1.11
Global burden of depressive disorders: the issue of duration. Br J Psychiatry (2002) 1.10
Statistical models in assessing fold change of gene expression in real-time RT-PCR experiments. Comput Biol Chem (2006) 1.09
Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. CNS Spectr (2005) 1.09
Accuracy of self-evaluation in adults with ADHD: evidence from a driving study. J Atten Disord (2005) 1.07
Efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: a drug-placebo response curve analysis. Behav Brain Funct (2005) 1.05
A retrospective claims database analysis to assess patterns of interstitial cystitis diagnosis. Curr Med Res Opin (2006) 1.04
Functional and psychosocial impairment in adults with undiagnosed ADHD. Psychol Med (2006) 1.04
An open-label trial of risperidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol (2005) 1.04
Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol (2004) 1.04
Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin (2008) 1.03
Training raters to assess adult ADHD: reliability of ratings. J Atten Disord (2005) 1.03
Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol (2003) 1.03
Comparison of the DSM-IV combined and inattentive types of ADHD in a school-based sample of Latino/Hispanic children. J Child Psychol Psychiatry (2005) 1.02
Deficient emotional self-regulation and adult attention deficit hyperactivity disorder: a family risk analysis. Am J Psychiatry (2011) 1.01
Application of a decision support tool for anticoagulation in patients with non-valvular atrial fibrillation. J Gen Intern Med (2008) 1.01
Assessing the validity of the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form in adults with ADHD. J Atten Disord (2007) 1.01
Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD. J Atten Disord (2009) 1.00
Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates. BMC Womens Health (2008) 0.99
Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol (2005) 0.99
Family based association study of pediatric bipolar disorder and the dopamine transporter gene (SLC6A3). Am J Med Genet B Neuropsychiatr Genet (2008) 0.99